

Modeling Biotransformation Using In Vitro Data on Parent-Metabolite Pairs within the ToxCast Phase I Chemical Set

Matt Martin

Society of Toxicology Annual Meeting March 18th 2009



This work was reviewed by EPA and approved for presentation but does not necessarily reflect official Agency policy. Mention of trade names or commercial products does not constitute endorsement or recommendation by EPA for use.

Overview

- ToxCast Overview
- ToxCast Biotransformation Overview
- Parent/Metabolite Analysis
- Assessment of Current Technology
- Conclusions & Next Steps

ToxCast


- Objectives

- In Vitro & In Silico Endpoints to Predict In Vivo Outcomes
- Use Resulting Predictions for Chemical Prioritization


- Challenges

- Accounting for **METABOLISM / BIOTRANSFORMATION**
- Extending from Animal to Human Toxicity Potential

ToxCast Phase I Assays 500 endpoints




ToxCast_320 Phase I Chemicals



ToxCast - Biotransformation

- ToxCast_320
 - 309 Unique Chemical Structures
 - 13 Parent-Metabolite Pairs
 - 1 Replicate (DBP)
 - 3 Parent Chemicals Share Common Metabolite (ETU)
- ToxCast Assays (500 Endpoints)
 - Cell-Based
 - HCS & Cytotoxicity
 - w/ & w/o Metabolic Competency
 - ADME (CYP Inhibition & Induction/Suppression)
 - NR (Binding & Transcription Factor Activation)

Profile of Parent/Metabolite Hits Across 320 Endpoints



Data Interpretation


- Parent Activity

- Are Positives Related to Parent Toxicity or Indicative of Metabolism?
 - Cyp Inhibition & Induction (associated w/ Downstream Toxicities & Metabolic Activation)
- Can Cytotoxicity Endpoints in Assays w/ & w/o Metabolic Capacity Serve as an Indicator of Metabolic Activation?
 - Sensitive Enough?
 - Specific Enough?


- Metabolite Activity

- Which Metabolite?
- Is Metabolite Activity $>$, $<$, or \neq Parent Activity?


Comparing Parent & Metabolite Bioactivity Profiles




Comparing Parent & Metabolite Bioactivity Profiles




Comparing Parent & Metabolite Bioactivity Profiles




Comparing Parent & Metabolite Bioactivity Profiles



ToxCast In Vitro Assays (320 Endpoints)



Parent-Metabolite Combinations (Parent IC50 – Metabolite IC50)



High Parent Activity vs. Low Metabolite Activity
Low Parent Activity vs. High Metabolite Activity

Highly Discriminating Assays

Parent vs. Metabolite

Top Assays w/ High Parent Activity & Low Metabolite Activity

CLZD_CYP2B6_6
NVS_ADME_hCYP2C19
ATG_PXR_TRANS
ATG_VDRE_CIS
BSK_3C_Proliferation
BSK_LPS_PGE2

Xenobiotic
Metabolism

CLMN_CellLoss_72hr
CLMN_MitoticArrest_72hr

HepG2

Top Assays w/ Low Parent Activity & High Metabolite Activity

NVS_ENZ_rAChE
BSK_BE3C_uPA
ATG_NFI_CIS
ATG_Myc_CIS
ATG_p53_CIS
BSK_hDFCGF_TIMP1



AChE
Inhibition

Chemical Class

- Organophosphorus
- Carbamate
- Thiocarbamate
- Organochlorine
- Conazole
- Triazine
- Phthalate
- Pyrethroid
- Other

ToxCast_320 Phase I Chemicals

Highly Discriminating Assays



Activity

HIGH METABOLITE
LOW PARENT

LOW METABOLITE
HIGH PARENT

13

Conclusions

- Chemical Perspective
 - Clear Differences in Parent-Metabolite Bioactivity
 - Both Increased & Decreased Metabolite Activity
 - Difficult to discern between:
 - Potentially Adverse Interaction
 - Metabolism-Related Interaction
 - Combination of Both
- Assay Perspective
 - Identified assays as indicators of metabolic activity
 - Identified assays susceptible to ‘false negatives’ if parent only tested
 - Parent chemical cytotoxicity results w/ metabolic capacity do not have similar results to metabolite cytotoxicity
- Next Steps
 - Identify and procure larger set of parent-metabolite pairs for ToxCast Phase II & Tox21
 - Further analyze data from existing cell-based systems w/ metabolic capacity
 - Explore new methods & technologies w/ metabolic components
 - Develop predictive models of biotransformation & subsequent activity/toxicity

Conceptual Model for Predicting Biotransformation & Subsequent Toxicities

